Is there a role for alpha1-blockers in treating double-J stent-related symptoms?

Deliveliotis, Charalambos; Chrisofos, Michael; Gougousis, Evagelos; Papatsoris, Athanasios; Dellis, Athanasios; Varkarakis, Ioannis

doi:10.1016/j.urology.2005.07.038

Cited by 120 publications

(112 citation statements)

References 27 publications

Supporting

Mentioning

105

Contrasting

Unclassified

Order By: Relevance

“…A Russian article published in Urologiia met the inclusion criteria according to the English abstract in PubMed; however it was subsequently excluded, since the full text could not be located (21). A total of 14 RCTs including 1,075 patients were included in the present meta-analysis (13,15,16,(22)(23)(24)(25)(26)(27)(28)(29)(30)(31)(32).…”

Section: Resultsmentioning

confidence: 99%

“…Table I outlines the characteristics of each study included in the present meta-analysis. All included studies were RCTs; eight studies were performed in Asia, (24)(25)(26)(27)(28)31,32) three in Europe (13,16,22), two in Africa (15,29), and one in America (23). Participant ages ranged from 17-87 and the follow up periods were 1-6 weeks.…”

Section: Resultsmentioning

confidence: 99%

“…sub-scores, five trials (15,26,27,29,32) employed voiding symptoms sub-scores, and seven trials (13,16,(22)(23)(24)(25)30) evaluated USSQ urinary symptoms scores in order to evaluate the effectiveness of α 1 -adrenoceptor antagonists as therapeutic agents for patients with USS. VAPS was adopted in nine studies (13,15,16,23,25,26,28,30,32) and USSQ pain score was applied in six trials (13,16,(22)(23)(24)(25) In eight studies, analgesics and/or antibiotics were used in all patients as a general therapy.…”

Section: Resultsmentioning

confidence: 99%

“…VAPS was adopted in nine studies (13,15,16,23,25,26,28,30,32) and USSQ pain score was applied in six trials (13,16,(22)(23)(24)(25) In eight studies, analgesics and/or antibiotics were used in all patients as a general therapy. No significant differences in the rates of employment and sexual activity were demonstrated between the treatment groups.…”

Section: Resultsmentioning

confidence: 99%

“…Additional methods, including the Visual Analog Pain Scale (VAPS), International Prostate Symptom Score (IPSS) and the Short-form 36 Health Survey Scale (SF-36) α 1 -blockers for the reduction of ureteric stent-related symptoms: A systematic review and meta-analysis have been applied to evaluate USS in relevant studies (14,15). Previous studies have demonstrated that α 1 -blockers have a significant impact on patients with USS (13,16). α 1 -blockers inhibit basal tone and decrease peristaltic frequency and amplitude, thus improving stone-free rate and shortening the time to stone expulsion in patients with ureteral stones.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

α1-blockers for the reduction of ureteric stent-related symptoms: A systematic review and meta-analysis

Zhang

Cheng

et al. 2015

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

Abstract. The present meta-analysis aimed to evaluate the current evidence for the use of α 1 -blockers in relieving ureteric stent-related symptoms (USS). Electronic databases, including PubMed, Embase and Cochrane Library, were searched and two independent reviewers identified relevant parallel randomized controlled trials (RCTs), assessed trial quality and extracted data. Review Manager (version 5.2) was used to conduct a meta-analysis of the data. Significant advantages were demonstrated in the treatment group based on International Prostate Symptom Score (IPSS), voiding symptom sub-scores [mean difference (MD), -2.66; 95% confidence interval (CI), (-4.36, -0.96)], Ureteral Stent Symptom Questionnaire (USSQ) urinary symptoms score (MD, -5.84; 95%CI, -9.35 to -2.33), IPSS quality of life score (MD, -1.46; 95%CI, -2.64 to -0.28) USSQ quality of life score (MD, -0.69; 95%CI, -1.10 to -0.28), USSQ pain score (MD, -3.97; 95%CI, -5.52 to -2.42), Visual Analog Pain Scale (MD, -1.53; 95%CI, -2.25 to -0.80) and USSQ general health score (MD, -1.82; 95%CI, -2.47 to -1.18). No significant differences were detected from the following results: IPSS storage symptom sub-score (MD, -0.93; 95%CI, -2.28 to 0.43), USSQ sexual matters score (MD, -0.10; 95%CI, -0.79 to 0.59), USSQ work performance score (MD, 1.64; 95%CI, and USSQ additional problems score (MD, -2.02; 95%CI, -4.55 to 0.52). However, significant between-trial heterogeneity was detected following statistical analysis and there were insufficient data to trace its source. The existing RCT data supported the hypothesis that α 1 -blockers beneficially influence pain, urinary symptoms and the quality of life of patients with an indwelling ureteral stent.

show abstract